REGLYDE
CLINICAL TRIAL
The World’s First Phase II and Phase III Clinical Trials on Computerized Yoga Technology for Alzheimer's
We’re excited to introduce the REGLYDE Phase II Clinical Trial, launching in June in the Czech Republic and Slovakia. This first-of-its-kind study explores whether machine-guided yoga-based movement can help slow cognitive decline in Alzheimer’s patients.
REGLYDE, an acronym for Reversing Glymphatic Dementia, reflects our mission to advance brain health through the integration of science and natural healing.
To evaluate the effectiveness of our moto-glymphatic therapy, we are conducting a 4-week Phase II clinical trial with 60 participants, and a 12-week Phase III clinical trial with 240 participants. These studies examine the therapy’s impact on brain toxin clearance, biomarkers of neurodegeneration, sleep quality, and cognitive function in patients with Alzheimer’s disease. Our objective is clear: to develop an effective, non-invasive, disease-modifying treatment.
The Power of the Glymphatic System
Scientists at Ciatrix have identified a previously unexplored link between natural spinal motion, respiration, neurological function, and brain health.
The foundation of REGLYDE lies in the glymphatic system, the brain’s innate waste-clearing mechanism. This system uses cerebrospinal fluid (CSF) to flush out toxins and metabolic byproducts (including proteins linked to Alzheimer’s disease) that can accumulate and damage brain cells. By augmenting CSF circulation and production, we believe it’s possible to support brain health and potentially reduce, halt, or even reverse the progression of cognitive decline.
Our research suggests that synchronizing spinal movements with respiration can significantly boost cerebrospinal fluid circulation, potentially increasing glymphatic system clearance by orders of magnitude—far exceeding the effects of any drug or molecule we’ve tested.
What Makes REGLYDE Unique?
Unlike traditional Alzheimer’s treatments that rely heavily on pharmaceuticals, the REGLYDE Clinical Study takes a different approach. It investigates how computer guided yoga-based movements—rooted in pranayama —can stimulate CSF flow and promote the brain’s natural cleansing process.
This method is comprehensive, inclusive, and empowering, offering a potential alternative or complementing existing interventions. In this study, we are using a computerized neuro-therapy device that synchronizes spinal movements with slow respiration to enhance cerebrospinal fluid circulation and achieve neuro-fluids coherence.
While Fluere™—a device developed by CIatrix for these clinical trials—plays an important role in our research, the heart of REGLYDE lies in yoga, the relaxation-based practice itself and its potential for Alzheimer’s care.
* Please note that Fluere™ is an investigational device that is not FDA-approved for Alzheimer’s disease treatment and will be studied in the REGLYDE Clinical Trial to evaluate its potential effects on cognitive decline in Alzheimer’s patients.
Why Are We Crowdfunding?
Because Together, We Can Make History
Crowdfunding allows us to democratize the fight against Alzheimer’s, placing the power to drive innovation into your hands.
We are prepared to fund smaller clinical trials internally, beginning with a Phase II study of 60 patients across three clinical sites. However, to achieve scientifically significant results that meet the standards of the FDA and other national health agencies, we need to expand our participant pool and replicate outcomes in multiple trial centers. Rather than waiting on traditional funding, we’re rallying a passionate community—people like you—who believe in bold, life-changing solutions. Every contribution directly supports this groundbreaking clinical study, covering participant recruitment, data analysis, regulatory approvals, and Fluere™ device development.
With your support, we can validate its potential, accelerate progress, and bring this revolutionary approach to those who need it most. Join us and be part of history!
We will be launching our crowdfunding campaign shortly — stay tuned!
StartUp Health Spotlights Ciatrix in the Fight Against Alzheimer’s
The Alzheimer’s Moonshot, led by StartUp Health in partnership with the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates Ventures, is advancing breakthroughs in Alzheimer’s prevention, diagnosis, and care. As part of this global initiative, Ciatrix is driving innovation alongside leading entrepreneurs, researchers, and funders, developing groundbreaking solutions with the support of StartUp Health. Ciatrix is proud to be part of this mission!
Join Us in This Transformative Journey
Ciatrix is launching an Indiegogo campaign to fund the REGLYDE Clinical Study and bring this vision to life. By supporting us, you’ll play a vital role in helping us pioneer this research and stay informed of our progress every step of the way. Together, we can explore a new frontier in Alzheimer’s care.